Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo : Reference Data

07/30/2021 | 12:09am EDT

TSE:4568

Reference Data

(Consolidated Financial Results for Q1 FY2021)

July 30, 2021

Daiichi Sankyo Co., Ltd.

Contents

1.

Consolidated Statement of Profit or Loss

P1

2.

Sheet to adjust Operating Profit to Core Operating Profit

P2

3.

Revenue of Global Products

P3

4.

Revenue by Business Units and Products

P4

5.

Consolidated Statement of Financial Position

P7

6.

Consolidated Statement of Cash Flows

P9

7.

Number of Employees

P10

8.

Capital Expenditure, Depreciation and Amortization

P10

9.

Summary of Product Outlines

P11

10.

Quarterly Data

P12

11.

Historical Data

P17

12.

Major R&D Pipeline (Innovative pharmaceuticals)

P21

1. Consolidated Statement of Profit or Loss

JPY Bn

Revenue

Cost of sales※1

Gross Profit

SG&A expenses※1

R&D expenses※1

Core Operating Profit

Other income※2

Other expenses※2

Operating Profit

Financial income/expenses

Share of profit or loss of investments accounted for using the equity method

Profit before tax

Income taxes

FY2020 Q1

FY2021 Q1

to revenue

Results

to revenue

Results

(vs. Forecast (%))

YoY

YoY (%)

100.0%

236.9

100.0%

264.1

26.7%

27.1

+11.4%

34.7%

82.2

32.2%

85.2

26.6%

2.9

+3.6%

65.3%

154.7

67.8%

178.9

26.7%

24.2

+15.6%

30.3%

71.8

30.8%

81.2

24.3%

9.4

+13.1%

20.6%

48.9

20.5%

54.0

20.3%

5.2

+10.5%

14.4%

34.1

16.5%

43.7

62.4%

9.6

+28.2%

0.1

2.1

2.0

0.0

0.0

-0.0

14.4%

34.1

17.3%

45.8

65.4%

11.6

+34.1%

7.2

1.3

-6.0

0.0

-0.0

-0.0

17.5%

41.4

17.8%

47.1

67.2%

5.7

+13.7%

9.6

11.8

2.3

Forex impact: +6.6

(USD: +0.9, EUR: +3.5, ASCA: +2.2)

Forex impact: +0.1

(USD: +0.4, EUR: -0.7, ASCA: +0.4)

Forex impact: +2.3

(USD: +0.4, EUR: +1.2, ASCA: +0.7)

Forex impact: +1.2

(USD: +0.4, EUR: +0.8, ASCA: +0.1)

Forex impact: +3.0

(USD: -0.2, EUR: +2.2, ASCA: +1.1)

  • Recognition of financial income due to decrease in contingent consideration of quizartinib acquisition -4.7 (FY2020)
  • Deterioration in forex gains/losses -0.6

FY2021

to revenue

Forecast

YoY

YoY (%)

100.0%

990.0

27.5

+2.9%

32.3%

320.0

-17.8

-5.3%

67.7%

670.0

45.2

+7.2%

33.7%

334.0

15.5

+4.9%

26.9%

266.0

38.6

+17.0%

7.1%

70.0

-8.9

-11.2%

-

-0.6

-

-15.6

7.1%

70.0

6.2

+9.7%

7.1% 70.0 -4.1 -5.6%

Profit for the year

13.4%

31.8

13.3%

35.2

70.4%

3.4 +10.7%

5.1%

50.0

-25.8

-34.1%

Profit attributable to owners of the Compan

y

13.4%

31.9

13.3%

35.2

70.4%

3.4 +10.6%

5.1%

50.0

-26.0

-34.2%

Tax rate

23.1%

25.2%

Overseas sales ratio

38.6%

44.7%

Currency Rate (Average)

Currency Rate (Average)

USD/JPY

107.62

109.49

105.00

EUR/JPY

118.47

131.95

120.00

Annual impact of one yen change

Forecast

USD

EUR

*This report is not subject to audit procedures.

Revenue

1.8 JPY Bn

0.9 JPY Bn

Operating Profit

-0.6 JPY Bn

0.3 JPY Bn

※1 Temporary gains and losses are excluded for cost of sales, SG&A expenses and R&D expenses

※2 See page 2 for the definition of temporary gains and losses and the adjustment of operating profit and core operating profit

1

2. Sheet to adjust Operating Profit to Core Operating Profit

FY2020 Q1 Results

Operating

Adjustment

Operating

JPY Bn

gains and losses

gains and losses

gains and losses

gains and losses related to loss

Profit (full)

related to sale of fixed

Others

Profit (Core)

related to restructuring

related to impairment,

compensation, reconciliation

assets

Revenue

236.9

236.9

Cost of sales

82.2

-

-

-

-

-

82.2

SG&A expenses

71.8

-0.0

-

0.0

-

-

71.8

R&D expenses

48.8

-0.1

-

-

-

-

48.9

Core Operating Profit

34.1

-0.1

-

0.0

-

-

34.1

Major Other income and Other expenses

Other income

0.1

-

-

-

-

0.1

(Cost of sales)

-

(SG&A expenses)

0.0

0.0

(R&D expenses)

0.1

0.1

Other expenses

0.0

-

0.0

-

-

0.0

(Cost of sales)

-

(SG&A expenses)

0.0

0.0

0.0

(R&D expenses)

-

Operating Profit (full)

34.1

-

-

-

-

-

34.1

FY2021 Q1 Results

Operating

Adjustment

Operating

gains and losses

gains and losses

gains and losses

gains and losses related to loss

JPY Bn

Profit (full)

related to sale of fixed

Others

Profit (Core)

related to restructuring

related to impairment,

compensation, reconciliation

assets

Revenue

264.1

264.1

Cost of sales

85.2

-0.0

-

-

-

-

85.2

SG&A expenses

79.1

-2.1

-

-

-

-0.0

81.2

R&D expenses

54.0

-0.0

-

-

-

-

54.0

Core Operating Profit

45.8

-2.1

-

-

-

-0.0

43.7

Major Other income and Other expenses

Other income

2.1

-

-

-

0.0

2.1

*1 Gains related to sale of Osaka logistics

(Cost of sales)

0.0

0.0

(SG&A expenses)

2.1

*1

0.0

2.1

(R&D expenses)

0.0

0.0

Other expenses

0.0

-

-

-

-

0.0

(Cost of sales)

-

(SG&A expenses)

0.0

0.0

(R&D expenses)

-

Operating Profit (full)

45.8

-

-

-

-

-

45.8

As an indicator of ordinary profitability, "core operating profit" which excludes temporary gains and losses (other revenue and other expenses) from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary gains and losses".

2

3. Revenue of Global Products

FY2020 Q1

FY2021 Q1

FY2021

Results

Results

(vs. Forecast (%))

YoY

YoY (%)

Forecast

Forecast

vs. Forecast

YoY

YoY (%)

JPY Bn

(as of Apr.)

(as of Jul.)

(as of Apr.)

Trastuzumab deruxtecan

anti-cancer agent

7.9

16.0

(21.8%)

8.1

+102.2%

84.0

73.1

-11.0

29.6

+68.1%

(HER2-directed antibody drug conjugate)

Product sales

5.2

13.0

(21.2%)

7.7

+148.5%

69.4

61.0

-8.4

30.9

+102.8%

Enhertu (JPN)

0.2

2.2

(16.2%)

2.0

+905.0%

13.4

13.4

-

9.0

+206.9%

Enhertu (US)

5.0

9.6

(22.6%)

4.6

+91.8%

50.4

42.4

-8.0

16.7

+65.0%

Enhertu (EU)

-

1.2

(23.6%)

1.2

-

5.4

5.1

-0.4

5.0

-

Enhertu (ASCA: Asia, South and Central America)

-

-

-

-

-

0.2

0.2

-

0.2

-

Upfront payment

2.5

2.5

(25.0%)

-

-

9.8

9.8

-

-

-

Regulatory milestone payment

0.2

0.6

(25.0%)

0.3

+146.0%

4.8

2.2

-2.6

-1.3

-37.2%

US HER2+ Breast Cancer 3L

0.2

0.2

(25.0%)

-

-

0.9

0.9

-

-

-

EU HER2+ Breast Cancer 3L

-

0.1

(25.0%)

0.1

-

0.5

0.5

-

-0.5

-50.0%

US HER2+ Gastric Cancer 2L+3L

-

0.2

(25.0%)

0.2

-

0.8

0.8

-

-0.8

-50.0%

US HER2+ or HER2 Mutant NSCLC 2L

-

-

-

-

-

2.6

-

-2.6

-

-

Datopotamab deruxtecan

anti-cancer agent

-

1.5

(25.0%)

1.5

-

5.8

5.8

-

1.9

+47.0%

(TROP2-directed antibody drug conjugate)

Upfront payment

-

1.5

(25.0%)

1.5

-

5.8

5.8

-

1.9

+47.0%

Edoxaban

anticoagulant

38.7

49.5

(25.5%)

10.8

+27.8%

188.4

194.0

5.6

28.1

+16.9%

Lixiana (JPN)

19.8

22.9

(24.8%)

3.1

+15.5%

90.4

92.1

1.7

14.7

+19.0%

Savaysa (US)

0.6

0.5

(25.2%)

-0.1

-9.4%

2.2

2.0

-0.2

-1.0

-32.0%

Lixiana (EU)

16.4

23.4

(26.1%)

7.0

+42.4%

84.6

89.7

5.0

13.0

+16.9%

Edoxaban (ASCA: Asia, South and Central America)

1.9

2.7

(26.9%)

0.8

+41.1%

11.1

10.2

-1.0

1.3

+14.8%

3

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 04:08:04 UTC.


© Publicnow 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
09:07aDAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72..
BU
09/17AstraZeneca Sees Positive Results for Enhertu Trial
DJ
09/16Japanese shares edge up as FOMO keeps rally alive
RE
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/07URAVAN MINERALS : Rises 20% as it Looks at Strategic Alternatives Because of Low..
MT
08/30Daiichi Sankyo Company, Limited Announces Results from the Multinational, Ran..
CI
08/20NIKKEI 225 : Declines 1% On Toyota, Pandemic Outlooks
MT
08/20Nikkei falls to 8-month low as Toyota drags peers, materials makers
RE
08/19Nikkei slides to 7-month low as Toyota drags peers, other cyclicals
RE
08/19Defence therapeutics selects the best 8 accumtm variants to optimize its adc ..
AQ
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Financials
Sales 2022 1 003 B 9 119 M 9 119 M
Net income 2022 58 841 M 535 M 535 M
Net cash 2022 630 B 5 731 M 5 731 M
P/E ratio 2022 92,0x
Yield 2022 0,95%
Capitalization 5 375 B 48 910 M 48 855 M
EV / Sales 2022 4,73x
EV / Sales 2023 4,44x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 804,50 JPY
Average target price 3 526,15 JPY
Spread / Average Target 25,7%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-20.66%48 910
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604